Seelos Therapeutics, Inc. (SEELQ)
| Market Cap | 14.00 -97.9% |
| Revenue (ttm) | 2.01M +76.0% |
| Net Income | 4.09M |
| EPS | 47.06 |
| Shares Out | 1.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 265 |
| Open | 0.00001 |
| Previous Close | n/a |
| Day's Range | 0.00001 - 0.00001 |
| 52-Week Range | 0.000001 - 0.0100 |
| Beta | 4.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Seelos Therapeutics
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007... [Read more]
Financial Performance
Financial StatementsNews
Seelos Announces Second Postponement of its Annual Meeting of Stockholders
NEW YORK , Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous syst...
Seelos Therapeutics Proxy statement: Proxy Filing
Seelos Therapeutics filed a proxy statement on October 24, 2024, providing details for shareholder voting and corporate governance matters.
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for ce...
Seelos Announces Postponement of its Annual Meeting of Stockholders
NEW YORK , Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sy...
Seelos Therapeutics Proxy statement: Proxy Filing
Seelos Therapeutics filed a proxy statement on September 26, 2024, providing details for shareholder voting and corporate governance matters.
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split
NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for ...
Seelos Therapeutics Registration statement: Registration Filing
Seelos Therapeutics filed a registration statement on September 25, 2024, providing details about a securities offering with the SEC.
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical compan...
Seelos Therapeutics Proxy statement: Proxy Filing
Seelos Therapeutics filed a proxy statement on August 20, 2024, providing details for shareholder voting and corporate governance matters.
Seelos Therapeutics Registration statement: Registration Filing
Seelos Therapeutics filed a registration statement on August 16, 2024, providing details about a securities offering with the SEC.
Seelos Therapeutics Quarterly report: Q2 2024
Seelos Therapeutics has published its Q2 2024 quarterly earnings report on August 14, 2024.
Seelos Therapeutics Proxy statement: Proxy Filing
Seelos Therapeutics filed a proxy statement on August 9, 2024, providing details for shareholder voting and corporate governance matters.
Seelos Therapeutics Registration statement: Registration Filing
Seelos Therapeutics filed a registration statement on June 14, 2024, providing details about a securities offering with the SEC.
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK , May 16, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for cen...
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
NEW YORK , May 14, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for cen...
Seelos Therapeutics Quarterly report: Q1 2024
Seelos Therapeutics has published its Q1 2024 quarterly earnings report on May 14, 2024.
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
- Richard Pascoe appointed Chairman of the Board of Directors to spearhead the ongoing business development discussions NEW YORK , April 29, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEE...
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
NEW YORK, March 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sys...
Seelos Therapeutics Annual report: Q4 2023
Seelos Therapeutics has published its Q4 2023 annual report on March 6, 2024.
Seelos Therapeutics Registration statement: Registration Filing
Seelos Therapeutics filed a registration statement on March 6, 2024, providing details about a securities offering with the SEC.
Seelos Therapeutics Registration statement: Registration Filing
Seelos Therapeutics filed a registration statement on February 2, 2024, providing details about a securities offering with the SEC.
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK , Jan. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervou...
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk of...
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous syste...
Seelos Therapeutics Proxy statement: Proxy Filing
Seelos Therapeutics filed a proxy statement on January 2, 2024, providing details for shareholder voting and corporate governance matters.